

## **Wockhardt Q1FY14 Net Sales at Rs.1358 crore and PAT at Rs.324 crore**

	Q1-FY14		Q1-FY13	FY13	
	Apr - Jun 2013		Apr - Jun 2012	Apr - Mar 2013	
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y
<b>Sales</b>	<b>1,358</b>	<b>1%</b>	<b>1,342</b>	<b>5,610</b>	<b>29%</b>
<b>R&amp;D *</b>	<b>98</b>	<b>326%</b>	<b>23</b>	<b>313</b>	
<b>R&amp;D % to Sales</b>	<b>7.2%</b>		<b>1.7%</b>	<b>5.6%</b>	
<b>Operating Profit</b>	<b>421</b>	<b>-13%</b>	<b>483</b>	<b>2,091</b>	<b>52%</b>
<b>Op. Profit Margins %</b>	<b>31.0%</b>		<b>36.0%</b>	<b>37.3%</b>	
<b>Profit After Tax</b>	<b>324</b>	<b>-14%</b>	<b>378</b>	<b>1,594</b>	<b>365%</b>
<b>PAT Margins</b>	<b>23.9%</b>		<b>28.2%</b>	<b>28.4%</b>	
<b>EPS</b>	<b>29.2</b>		<b>34.1</b>	<b>143.3</b>	<b>360%</b>

*\* Q1FY13 R&D expenses do not include the product development expenses as the same were being capitalised till Jun-13. On a like to like basis, R&D expenses for Q1FY13 would have been Rs.64 crore and resultant Operating Profit & PAT for Q1FY13 would have been Rs.442 crore and Rs.325 crore respectively.*

### **Quarter ended 30<sup>th</sup> June 2013**

Consolidated revenue for the quarter was Rs. 1358 crore and Profit After Tax was at Rs.324 crore which represents about 24% of Profit After Tax Margins.

The company increased its Research spent significantly and the same is now at 7.2% to sales at Rs.98 crores and including capital expenditure is at 7.7% to sales for the quarter.

Wockhardt filed 4 new product applications with USFDA during the quarter. Cumulative products pending approval with USFDA stands at 50 as on June 2013.

Wockhardt also filed for 27 patents during the quarter taking the cumulative filings to 1773 and has been granted 11 patents during the year taking the cumulative patents granted to 228.

### Capex

Capital expenditure of Rs.68 crore was incurred during the quarter.

### Business Highlights

Wockhardt's International Business contributed 82% of the Total Revenues during the quarter.

Wockhardt's US business recorded a growth of 11% in Q1FY14 and contributed 53% of the Global Revenues for Wockhardt

The UK business recorded a growth of 1% in Q1FY14. The Irish market recorded a decline of 31% in Q1FY14.

The India business grew by 3% and the Emerging Markets business declined by 28% in Q1FY14.

Wockhardt Limited has organized a conference call and webcast for investors and analysts on Wednesday, August 14, 2013 from 4.30pm – 5.30pm IST. The details of the webcast and conference call are as follows:

<b>Timing</b>	: 04:30 pm IST on Wednesday, August 14, 2013
<b><sup>1</sup>Webcast link</b>	: <a href="http://cs3-ipresent.choruscall.com/FlexPresenter">http://cs3-ipresent.choruscall.com/FlexPresenter</a>
<b><sup>1</sup>Webcast user-name</b>	: <your name>
<b><sup>1</sup>Webcast passcode</b>	: 6278924
<b><sup>2</sup>Conference dial-in Primary number</b>	: +91 22 3065 2574 / +91 22 6629 5806
<b>Hong Kong Local Access Number</b>	: 800 964 448
<b>Singapore Local Access Number</b>	: 800 101 2045
<b>UK Local Access Number</b>	: 0 808 101 1573
<b>USA Local Access Number</b>	: 1 866 746 2133
<b>Replay Facility</b>	: Available until August 19, 2013 on + 91 22 3065 1212 Play Back ID – 190813# Replay will be available 2 hours after the call ends

<sup>1</sup>For viewing the presentation while it is being discussed by the management

<sup>2</sup>For audio and the question and answer session

**PRESS RELEASE**



**Wockhardt Limited**

| Wockhardt Towers |  
| Bandra Kurla Complex |  
| Mumbai 400 051 | India |  
| Tel.: +91-22-2653 4444 |  
| [www.wockhardt.com](http://www.wockhardt.com)

---

**About Wockhardt :**

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 607 scientists, of whom 80 are doctorates. In all, Wockhardt has 228 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8600 people from 21 different nationalities.